Isabel is Co-Fund Manager for Aviva Investors’ European Real Estate Long Income Fund (E-RELI Fund). She is responsible for supporting the Fund Manager in delivering the Fund’s strategy including progress of asset management and value-add initiatives, and sourcing and managing acquisitions for the Fund. Isabel is also part of the dedicated Real Estate Long Income Origination Team where her role is to source and create investment opportunities across a variety of assets in the UK and European markets.
Experience and qualifications
Prior to joining Aviva Investors, Isabel worked at PwC where she spent eight years with their real estate restructuring and corporate finance teams, advising on a range of debt and equity transactions in the UK and Europe.
Isabel holds a BSc (Hons) from Bristol University and an MA from Cass Business School. She is a qualified Chartered Surveyor.
You might also be interested in
Zero-COVID: China’s costly policy error
10 Aug. 2022
Beijing’s ideological battle to stamp out COVID-19 appears increasingly misguided as the rest of the world learns to live with the virus. But the impact of China’s approach will be felt far beyond its borders.
Global equity income Q&A: Richard Saldanha on the outlook for dividends and growth
3 Aug. 2022
The lead manager of our Global Equity Income strategy discusses risks and opportunities for income-seeking investors in a turbulent time for markets.
The AIQ Podcast: Taking stock of nature risk
15 Jul. 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
UK Equity Income: Five questions with Chris Murphy
15 Jul. 2022
The manager of our UK Equity Income strategy explains why investors need to change their mindsets about what to pay for growth and cautions against buying yield for its own sake.
Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun. 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
UK Equities: Five questions with Charlotte Meyrick and Trevor Green
14 Jun. 2022
Charlotte Meyrick and Trevor Green explain why 2022 has all been about getting your sector calls right in UK equities.
What does the data say? Where have the safe havens gone?
27 May 2022
In this month’s instalment of our visual series on topical themes, we look at how various asset classes are holding up in a turbulent year for financial markets.
Life force: Why nature matters
12 May 2022
Growing awareness that natural systems are stressed or even close to breakdown is prompting asset managers to look closely at nature-based risks and investee companies to understand their environmental impacts and dependencies.
Back to nature: Why we must act now on the biodiversity crisis
31 Mar. 2022
In an age of mass extinctions, policymakers, businesses and financial institutions are beginning to acknowledge the risks associated with biodiversity loss, along with the opportunities that arise from nature-positive solutions.
Now for the hard part…..The challenge of delivering net zero
29 Mar. 2022
More than one fifth of the world’s largest listed companies have committed to net-zero targets, but few have detailed roadmaps to get there. Mirza Baig considers the challenges for investors managing transition pathways.
Ukraine-Russia crisis: The implications for global equities
29 Mar. 2022
Our global equities team discuss the main direct and indirect consequences of the Ukraine-Russia crisis for stocks.
Politics, activists and ESG: The outlook for UK equities
10 Mar. 2022
We bring together members of our UK equities team to discuss the key opportunities and risks in the market.
China, inflation and politics: Three reasons for EM turbulence
24 Feb. 2022
Emerging market assets have underperformed developed market peers over the past decade. While this has led to valuation gaps, selectivity will be critical, argues David Nowakowski.
The great digital detox
4 Feb. 2022
From Russian hackers interfering in foreign elections to high-profile corporate breaches, people are waking up to some harsh realities around data. We look at what the European call for a ‘Magna Carta’ for data has led to, and explore the investment implications of the growing scrutiny over data privacy.
Where the wild things are: Why investors should care about natural capital
14 Dec. 2021
Finance must wake up to the risks associated with biodiversity loss and the opportunities that arise from nature-friendly solutions, argue Eugenie Mathieu, Julie Zhuang and Jonathan Toub.
Waste not, want not: An investor’s guide to the circular economy
10 Dec. 2021
Using the examples of electronics, food, autos and fashion, we explore the benefits of, and challenges to achieving, a more circular economy.